The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer

BACKGROUND: Despite recent advances in treating non‐small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs), their role in ALK‐positive NSCLC patients is unclear. We investigated the efficacy of ICIs in patients with ALK‐positive NSCLC. METHODS: Between 2011 and 2018, a total of 14 A...

Descripción completa

Detalles Bibliográficos
Autores principales: Heo, Ja Yoon, Park, Changhee, Keam, Bhumsuk, Ock, Chan‐Young, Kim, Miso, Kim, Tae Min, Kim, Dong‐Wan, Kim, Se Hyun, Kim, Yu Jung, Lee, Jong Seok, Heo, Dae Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825904/
https://www.ncbi.nlm.nih.gov/pubmed/31509890
http://dx.doi.org/10.1111/1759-7714.13195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6825904/
https://www.ncbi.nlm.nih.gov/pubmed/31509890
http://dx.doi.org/10.1111/1759-7714.13195

Ejemplares similares